India, May 17 -- Regeneron Pharmaceuticals Inc. (REGN) announced results from its Phase 3 trial evaluating two dose levels of fianlimab, a LAG-3 inhibitor, in combination with cemiplimab, a PD-1 inhibitor, as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma. The study did not achieve statistical significance for the primary endpoint of progression-free survival (PFS) improvement compared with pembrolizumab monotherapy.
No new safety signals were identified with the fianlimab combination. However, a numeric improvement of 5.1 months in median PFS was observed for the high-dose fianlimab combination compared to pembrolizumab.
A separate Phase 3 head-to-head trial is ongoing, evaluating the high-d...